What You Should Know:
– RapidAI, a global leader in AI-powered solutions for combating life-threatening vascular diseases, announced today the FDA 510(k) clearance for its innovative AngioFlow™ by RapidAI solution.
– The technology empowers interventional care teams with real-time, AI-driven insights directly within the interventional suite, aiming to improve patient outcomes for stroke and other vascular emergencies.
Faster, More Informed Decisions in Stroke Care
Stroke is a time-sensitive medical emergency where rapid intervention is crucial for minimizing brain damage and long-term disability. AngioFlow™ by RapidAI addresses this critical need by leveraging validated deep learning AI to generate clear, easy-to-understand perfusion maps within minutes. These maps visualize areas of reduced blood flow in the brain, allowing specialists to make faster and more informed decisions regarding treatment strategies.
Key Benefits of AngioFlow™ by RapidAI
- Improved Clinical Confidence: Real-time AI insights directly within the interventional suite enhance physician confidence during critical procedures.
- Enhanced Workflow Efficiency: Streamlines workflow by potentially reducing the need for redundant imaging, saving valuable time in patient care.
- Reduced Healthcare Costs: Minimizes unnecessary imaging, particularly beneficial in rural facilities and large hospital networks with long transfer times.
- Potentially Improved Patient Outcomes: Faster and more informed treatment decisions can lead to better patient outcomes.
Enhancing Vascular Care with AI
AngioFlow™ by RapidAI represents a significant leap forward in AI-powered solutions for vascular care. This innovative tool empowers healthcare professionals with real-time, actionable intelligence, enabling them to deliver the best possible care to stroke and other vascular disease patients.
“We are pleased to expand our stroke AI imaging portfolio, the broadest in the industry, to include this new module. With AngioFlow™ by RapidAI, we can now support stroke AI imaging along the entire patient pathway, from the initial non-contrast CT scan all the way to the interventional suite,” said Karim Karti, CEO of RapidAI. “Already registered and used in Japan and Europe, we believe this technology will make a significant difference in the lives of U.S. stroke patients.”
